EUCTR2008-006414-19-GB进行中（未招募）1 期
Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-a in patients with advanced renal cell carcinoma. - DCE-MRI changes in tumour vaculature with Bevacizumab and Interferon in advanced RCC
East and North Hertfordhsire NHS Trust0 个研究点目标入组 30 人开始时间: 2009年4月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written informed consent (informed consent document to be approved by the institution’s Independent Ethics Committee and consent obtained prior to any study-specific procedure)
- •2. Male or female subjects > 18 years
- •3. Patients with previously untreated metastatic (stage IV) or locally advanced (inoperable stage III), renal cell carcinoma
- •4. Subject with histologically and/or cytologically confirmed, advanced (stage IV) RCC, of which a majority component of conventional clear-cell type is mandatory. Tumours of mixed histology should be categorized by the predominant cell type.
- •5. Good or intermediate prognosis disease as defined by Motzer score.
- •6. RECIST measurable lesion(s), which must be amenable to DCE-MRI scanning
- •7. Life expectancy of at least 12 weeks
- •8. Eastern Co-operative Oncology Group (ECOG) performance status 0-2
- •9. Adequate haematological function:
- •10. Adequate liver function:
- •11. Adequate renal function:
- •12. International normalised ratio (INR) =1.5 within 7 days prior to enrolment.
- •13. Women of childbearing age must have a negative pregnancy test and must use adequate contraception during the treatment phase of the study and for 9 months afterwards. Women who wish to breastfeed are not eligible for the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Diagnosis of brain metastasis.
- •2. Major surgery (incl. open biopsy) or radiation therapy within 28 days prior to enrolment (palliative radiotherapy to painful bone lesions is allowed within 14 days prior to enrolment).
- •3. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to enrolment
- •4. Significant cardiovascular disease defined as congestive heart failure (NYHA Class II, II, or IV), unstable angina pectoris, or myocardial infarction within 6 months prior to enrolment.
- •5. Inadequately controlled hypertension
- •6. History of stroke or transient ischemic attack within 6 months prior to enrolment
- •7. Significant vascular disease (e.g., aortic aneurysm, aortic dissection), or symptomatic peripheral vascular disease
- •8. Evidence or history of recurrent thromboembolism (>1 episode of DVT/PE) during the past 6 months, bleeding diathesis or coagulopathy
- •9. Chronic daily intake of aspirin >325 mg/day or clopidogrel >75 mg/day, or steroids (prednisone > 12.5 mg/day or dexamethasone > 2 mg/day).
- •10. History of abdominal or tracheo-oesophagel fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrolment
- •11. Serious, non-healing wound, ulcer, or bone fracture
- •12. Pregnant or breast feeding mothers
- •13. No contraindication to MRI scanning e.g. no history of claustrophobia, metal fragment implantation.
- •14. Current active second malignancy other than non-melanoma skin cancers and post-treatment for localized prostate cancer. Patients are not considered to have a currently active malignancy if they are in complete remission for >3 years prior to study
- •15. Patients with a history of allergic reactions to contrast agents
- •16. Patients with gross ascites
- •17. Seizure disorder requiring medication
- •18. HIV/Hep B/Hep C/ other infection >CTC 2; active clinically serious bacterial or fungal infections (> CTC 2)
- •19. Other investigational drug during trial or within 30 days
- •20. Any prior anti-angiogenic therapy within 6 months
- •21.Any other significant medical illness or medically significant abnormal laboratory finding that would, in the investigator’s judgment, make the patient inappropriate for this study, or would increase the risk associated with the patients’ participation in the study.
研究者
相似试验
进行中（未招募）
不适用
Differences in dynamic contrast-enhanced (DCE) MRI measurements using Magnevist (Gd-DTPA) and Vas-ovist in patients with untreated squamous cell cervical carcinoma. - NDntreated squamous cell cervical carcinoma(SCCC).MedDRA version: 9.1Level: HLTClassification code 10029109Term: Cervix neoplasmsEUCTR2008-002958-37-ITISTITUTO EUROPEO DI ONCOLOGIA
招募中
不适用
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the BodyHead and Neck CancerNCT03145077M.D. Anderson Cancer Center1,400
已完成
不适用
Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical ResectionSoft Tissue SarcomaNCT01575951University of Utah16
已完成
不适用
DCE-MRI for Assessment of Response to TACE of HCCCarcinoma, HepatocellularNCT02878109Centre hospitalier de l'Université de Montréal (CHUM)40
已完成
2 期
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-alpha in patients with advanced renal cell carcinomaAdvanced or metastatic renal cell carcinomaMalignant neoplasm of kidney, except renal pelvisCancerISRCTN08193901East and North Hertfordshire NHS Trust (UK)30